TrialJournal of Crohn's & colitis2024

Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies.

Jean-Frederic Colombel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.